BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Argo Biopharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Argo Biopharmaceutical's
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07235046-1076@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:BW-20829: Phase 2 readout est. (NCT07235046)
DESCRIPTION:BW-20829\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Study of DII235 in Adults With Elevated Lipoprotein(a)\nEstimated 
 primary completion: 26 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bw-20829#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07235046
URL:https://assetmemo.bio/drug/bw-20829#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
